Study of Denmark's Mandatory Etanercept Switch Finds No Obvious Changes in Healthcare Utilization, Costs - The Center for Biosimilars

Study of Denmark's Mandatory Etanercept Switch Finds No Obvious Changes in Healthcare Utilization, Costs  The Center for Biosimilars

Researchers examining the mandatory switch of patients with rheumatoid arthritis (RA) from the originator etanercept (Enbrel) to the biosimilar etanercept ...



Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network